newsfilter
← Earnings
Earnings Releases·

PMV Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Net loss for the quarter ended September 30, 2026, was $34.4 million, up from $21.1 million in the prior year period, driven by a $12.8 million non-cash loss related to warrant liability changes; cash and equivalents decreased to $108.5 million from $112.9 million as of year-end 2025.
  • The Company completed a $50 million public offering in August 2026, extending its cash runway into the first quarter of 2028, while total liabilities rose to $54.3 million primarily due to the recognition of a $43.6 million warrant liability.
  • Updated interim data from the registrational PYNNACLE Phase 2 trial showed a 46% Overall Response Rate (35/76 patients) with a median duration of response of 10.0 months, supporting the planned New Drug Application (NDA) submission for platinum-resistant/refractory ovarian cancer in Q1 2027.
  • Management appointed Philip Herman as Chief Commercial Officer and Matt Eckler, Ph.D., to the Board of Directors, while R&D and G&A expenses for the quarter decreased to $16.1 million and $4.0 million, respectively.
Company
PMV PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology